Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
Felicia Zhang Perkins, Xiuli Zhang, Yik Yeung Lawrence Yu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated the safety and immunogenicity of synthetic long peptide and DNA personalized cancer vaccines in patients with resected pancreatic ductal adenocarcinoma. The study found that these vaccines were well tolerated and induced neoantigen-specific T cell responses. Patients receiving personalized cancer vaccines showed a trend toward improved median overall survival of 4.4 years compared to 3.5 years in a matched cohort.
Key findings
- Personalized cancer vaccines were well tolerated with no grade ≥3 adverse events.
- Neoantigen-specific T cell responses were confirmed through various immunological assays.
- Patients receiving personalized cancer vaccines had a median overall survival of 4.4 years compared to 3.5 years in a matched cohort.
Why it matters
The study highlights the potential of personalized cancer vaccines to elicit specific immune responses in pancreatic cancer, a disease typically resistant to standard immunotherapies. Understanding these responses may inform future treatment strategies.